The invention relates to a method, and to the corresponding dosage form thereof, for the treatment of motor dysfunction associated with Parkinson's disease, using a drug treatment against Parkinson's disease, and/or with dementia associated with Parkinson's disease, for example, using levodopa therapy. The invention involves the combined administration of an antagonist of the NMDA receptor and an antidepressant, for example a combination of amantadine and citalopram or venlafaxine, or an antagonist of the NMDA receptor and an anxiolytic agent, for example amantadine and buspirone or trazodone, in order to improve unwanted tremors, akinesia, dyskinesia or bradykinesia associated with one or more different disorders or diseases. According to the invention, the drugs can be used in a single dosage form. One embodiment of the invention comprises a combined dosage form which contains each drug in controlled-release form. Another embodiment thereof comprises a combined dosage form which provides the controlled release of an antagonist of the NMDA receptor and the rapid release of a neuroactive agent following administration to the patient.
DRUG COMBINATION FOR MOTOR DYSFUNCTION IN PARKINSON'S DISEASE